timothy sykes logo
SPRY Slides As CVS Caremark Delay Triggers Class Action Hit Thumbnail
G Google News

SPRY Slides As CVS Caremark Delay Triggers Class Action Hit

JACK KELLOGG•UPDATED AUG. 15, 2026, 11:05 AM ET
Reviewed by Ellis Hobbsand Fact-checked by Matt Monaco

ARS Pharmaceuticals Inc. stocks have been trading down by -7.38 percent following FDA-related setbacks dampening investor confidence.

What Traders Need To Know

  • A securities class action targets ARS Pharmaceuticals Inc. (SPRY) over claims it misled on the timing and certainty of CVS Caremark insurance coverage for neffy.
  • On 2026/06/24, the company revealed CVS Caremark delayed its neffy coverage decision to at least 2027/01, missing the guided 2026/07/01 start.
  • After that update, SPRY dropped roughly 23.9–24% in a single session, signaling a sharp reset in expectations.
  • The complaint alleges prior statements understated risks around CVS Caremark formulary decisions, inflating SPRY’s share price.
  • The putative class period runs from 2026/03/09 to 2026/06/24, flagging management commentary in that window as legally sensitive.

Candlestick Chart

Weekly Update Aug 10 – Aug 14, 2026: On Saturday, August 15, 2026 ARS Pharmaceuticals Inc. stock [NASDAQ: SPRY] is trending down by -7.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – negative

ARS Pharmaceuticals (SPRY) sits in an emerging, single‑asset–heavy position within biotech, with neffy as the core value driver. Fundamentals are characteristic of a commercial‑stage, subscale specialty pharma: 74% gross margin but deeply negative EBITDA margin (~‑205%) and ROE (~‑136%), with LTM revenue of ~$84 million growing rapidly from a low base. Liquidity is solid near term (current ratio ~4.9, cash and short‑term investments ~$144 million), but quarterly operating cash burn of ~$61 million makes eventual dilution or refinancing likely.

Technically, SPRY shows a fragile post‑gap structure after the ~24% one‑day drop tied to the CVS Caremark coverage delay. The weekly tape between 5.91 and 6.16 followed by an air‑pocket low at 4.90 and a weak bounce to 5.65 indicates a developing downtrend with heavy event‑driven volume on the breakdown and lighter volume on rebounds. The actionable level is $4.90: below it, short bias is favored; above $6.10, a tactical long squeeze toward $6.75–7.00 becomes viable.

Catalysts are now dominated by litigation and payer‑access credibility risk. The securities class action over alleged misstatements on CVS Caremark timing, and the deferral of broad coverage to at least January 2027, push out monetization versus prior guidance and materially underperform typical Healthcare and Biotechnology & Life Sciences peers on governance and near‑term growth visibility. With legal overhang, high burn, and delayed upside, risk‑reward skews negatively; I see fair value closer to $4.50–5.00 with resistance at $6.00–6.25 and support at $4.75.

More Breaking News

Quick Financial Overview

SPRY is trading in the mid‑$5s after heavy selling pressure tied to the CVS Caremark delay and the new securities class action. Weekly data show a failed push above $6.10 on 2026/08/13, which collapsed intraday toward $4.90 before stabilizing near $5.25 and then rebounding to about $5.65. The intraday 5‑minute snapshot around $5.10–$5.84, closing near $5.65, confirms wide ranges and emotional trading, typical after a shock event.

Fundamentally, ARS Pharmaceuticals Inc. is still in heavy build‑out mode. The company posted about $84.28M in revenue, with a strong 74.1% gross margin, but extremely negative operating margins near -205% and a recent quarterly net loss of roughly $62.34M. Cash burn is meaningful, with operating cash flow at about -$60.93M for the quarter and free cash flow matching that outflow, so the business is not self‑funding yet.

On the balance sheet, SPRY carries total assets of about $249.50M against total liabilities near $236.98M, leaving modest equity of roughly $12.51M. Liquidity is solid for now, with a current ratio of 4.9 and quick ratio of 4.6, plus around $143.85M in cash and short‑term investments. However, leverage is not trivial, with total debt‑to‑equity at 1.57 and long‑term debt near $96.68M, so prolonged delays in payer coverage for neffy could matter for future capital needs.

Conclusion

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”